Comparative Evaluation of Antimicrobial Efficacy, Clinical and Radiographic Success of Calcium Hydroxide, Chlorhexidine, and Modified Triple Antibiotic Paste in Different Combination Forms As Intracanal Medicaments Against Enterococcus Faecalis in Primary Teeth
Launched by MAHY ABDEL RAOUF ALY KAMAR · Oct 1, 2024
Trial Information
Current as of June 29, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is designed to compare the effectiveness of different treatments used inside decayed primary (baby) teeth that have become infected. Specifically, it looks at three types of medications: Calcium Hydroxide, Chlorhexidine, and Modified Triple Antibiotic Paste. The goal is to see which combination of these treatments works best to reduce harmful bacteria, particularly a type called Enterococcus faecalis, and to determine how well these treatments help the tooth heal over a year.
To be eligible for this study, children must have certain issues with their primary molars, such as severe decay leading to pulp necrosis (dead nerve tissue), and they must show signs of pain. However, children who have health problems that make them uncooperative, or who have teeth that are too damaged or already need to be removed, will not be included. Participants can expect to undergo a procedure called pulpectomy, where the infected pulp is removed and treated, and they will be followed up for one year to monitor the tooth's healing process. Remember, this trial is not yet recruiting participants, so more information will be available in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • • Primary molars necessitating pulpectomy diagnosed with deep dental caries with pulp necrosis, apical periodontitis and periapical pathosis or both.
- • Non-Vital pulps.
- • Negative response to hot or cold pulp tester (ethyl chloride spray ).
- • Decayed tooth with spontaneous unprovoked long dull aching pain showing signs of necrosis of the pulp
- Exclusion Criteria:
- • Medically compromised and uncooperative children
- • Tooth indicated for extraction
- • Mobile teeth (Miller's Grade 2 or more)
- • teeth with more than two-thirds of root resorption
- • previous endodontic treatment
About Mahy Abdel Raouf Aly Kamar
Mahy Abdel Raouf Aly Kamar is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative trial design and rigorous scientific methodologies. With a focus on ethical practices and regulatory compliance, the organization collaborates with a diverse network of healthcare professionals and institutions to facilitate the development of new therapies. Leveraging extensive experience in clinical operations, Mahy Abdel Raouf Aly Kamar aims to drive meaningful contributions to the healthcare landscape, ensuring that each study is conducted with the highest standards of quality and integrity.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported